Moreover, Xie et al. (2021) concluded that IGF2BP3 was involved in the metabolism of IGF2BP3/CDKN2B-AS1/NUF2 axis, this genetic mechanism suggests that IGF2BP3 may be an ideal tumor marker and therapeutic target for ccRCC in the future. The gene discussed is NUF2; the disease is neoplasm.